Name of the Procedure:

Commonly known as "Golimumab Injection" or "Simponi Aria IV," and technically referred to by its HCPCS code "J1602."

Summary

Golimumab injection is a medical procedure involving the intravenous administration of the medication golimumab, which is used to reduce inflammation in certain autoimmune conditions.

Purpose

This procedure targets autoimmune conditions like rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. The goal is to alleviate inflammation, reduce symptoms, and improve the patient's overall quality of life.

Indications

• Diagnosed with moderate to severe rheumatoid arthritis.
• Cases of ankylosing spondylitis resistant to conventional treatments.
• Psoriatic arthritis not adequately controlled by other medications.
• Other autoimmune disorders as specified by a healthcare provider.

Preparation

• Fasting is generally not required.
• Medication adjustments will be advised by the healthcare provider.
• Blood tests or imaging studies may be required before the procedure to assess overall health status.

Procedure Description

1. Patient checks in and is seated or lies down comfortably.
2. An intravenous (IV) line is placed in the patient's arm or hand.
3. Golimumab is administered through the IV over a period of time, which is monitored by medical staff.
4. The IV is removed once the medication infusion is complete. Tools: IV catheter, infusion pump, sterile dressings. No anesthesia or sedation is required.

Duration

The procedure typically takes between 30 to 60 minutes.

Setting

This procedure is usually performed in an outpatient clinic or a hospital infusion center.

Personnel

• A registered nurse (RN) or medical assistant to administer the IV.
• A healthcare provider such as a rheumatologist to oversee the procedure.

Risks and Complications

Common risks:

• Mild allergic reactions (rash, itching) Rare risks:
• Serious infections due to immunosuppression
• Reactivation of latent tuberculosis
• Infusion reactions (fever, chills)
• Managing complications: Immediate medical intervention and possible medication adjustments.

Benefits

Expected benefits include reduced inflammation, decreased pain, improved joint function, and overall enhanced quality of life. Benefits may be experienced within weeks of the first dose.

Recovery

• Minimal recovery time; patients can typically return to regular activities shortly after the procedure.
• Follow-up appointments as advised by the healthcare provider.
• Regular monitoring for any side effects or infections.

Alternatives

• Other biologic agents (e.g., etanercept, adalimumab)
• Non-biologic DMARDs (Disease-Modifying Anti-Rheumatic Drugs)
• Physical therapy and lifestyle modifications
• Pros and cons: Each alternative has its specific benefits and potential side effects; discussing these with a healthcare provider is essential to finding the best treatment plan.

Patient Experience

During the procedure:

• Mild discomfort from the IV line insertion.
• Monitoring by medical staff throughout the infusion. After the procedure:
• Minimal side effects in most cases.
• Detailed post-procedure care and symptom management guidance will be provided.
• Pain management: Over-the-counter pain relievers for any mild discomfort.

This markdown text provides a comprehensive overview of the "Injection, golimumab, 1 mg, for intravenous use (J1602)" procedure, suitable for both medical professionals and patients seeking a clear understanding of the treatment.